The Manufacturers Life Insurance Company Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

The Manufacturers Life Insurance Company reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,242,331 shares of the biopharmaceutical company’s stock after selling 518,517 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Gilead Sciences were worth $173,144,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of GILD. Norges Bank purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $2,617,152,000. Boston Partners purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $517,808,000. Massachusetts Financial Services Co. MA grew its position in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after buying an additional 4,113,999 shares during the period. Bank of America Corp DE grew its position in Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after buying an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after buying an additional 2,113,692 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock valued at $8,687,140 over the last three months. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Royal Bank Of Canada lowered their price target on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Monday, July 6th. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $158.30.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $134.32 on Wednesday. The firm has a market cap of $166.77 billion, a P/E ratio of 18.30 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company’s 50 day moving average is $129.64 and its 200-day moving average is $135.75. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the firm earned $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley maintained an Overweight rating on Gilead and only modestly reduced its price target to $165 from $166, implying substantial potential upside based on the recent trading level. The endorsement supports sentiment toward Gilead’s valuation and outlook. Benzinga analyst update
• Positive Sentiment: Gilead’s shares outperformed the market during the latest session, suggesting investors may be responding to the company’s defensive profile, strong profitability and established product portfolio. Its most recent reported quarter exceeded consensus estimates for both earnings and revenue, providing a supportive backdrop. Gilead Sciences outperforms the market
• Neutral Sentiment: Broader biopharmaceutical industry developments, including digital bioprocessing and prediction-market discussions related to drug research, do not appear to create a direct near-term catalyst for Gilead. Bioprocessing Summit 2026
• Negative Sentiment: Zacks expects Gilead to report a decline in upcoming earnings and says the company lacks the combination of positive earnings revisions and estimates typically associated with a likely earnings beat. This could limit upside or increase volatility ahead of the results. Gilead earnings expectations

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.